Contura Holdings

Contura is a medical technology company that specializes in the development and commercialization of innovative hydrogel products for soft tissue augmentation. The company's proprietary polyacrylamide hydrogel technology is used to create non-resorbable, biocompatible implants that integrate with surrounding tissue. Its flagship product, Bulkamid, is a leading treatment for female stress urinary incontinence and was the primary driver behind the company's acquisition by Axonics in 2021 for $200 million. Contura also markets Arthrosamid, an injectable hydrogel therapy designed to provide long-term pain relief for patients suffering from knee osteoarthritis.